ClinicalTrials.gg

Program

DA-1229_01

Its studies are mostly in Diabetes Mellitus, Type 2, led by Dong-A ST.

Furthest: phase 1, since Jun 11, 20144 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Dong-A ST40 open or runningphase 1since Jun 11, 2014Jun 11, 2014none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 11, 2014First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT02167061 · 64 enrolled · Korea, Republic of
  2. Feb 24, 2015Phase 1 study in Diabetes Mellitus, Type 2NCT02375139 · 36 enrolled · Korea, Republic of
  3. Dec 9, 2025Phase 1 study in HealthyNCT07297940 · 42 enrolled · South Korea
  4. Jan 6, 2026Phase 1 study in HealthyNCT07342062 · 36 enrolled · South Korea

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07342062Healthy · South Korea1CompletedFeb 14, 202636
NCT07297940Healthy · South Korea1CompletedJan 31, 202642
NCT02375139Diabetes Mellitus, Type 2 · Korea, Republic of1CompletedJun 201536
NCT02167061Diabetes Mellitus, Type 2 · Korea, Republic of1CompletedNov 201464

How it is read

Names in the registry

  • “DA-1229_01”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.